Compare IDR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | DSGN |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 418.1M |
| IPO Year | N/A | 2021 |
| Metric | IDR | DSGN |
|---|---|---|
| Price | $38.02 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.50 | $13.50 |
| AVG Volume (30 Days) | 425.5K | ★ 538.4K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.70 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $35,424,313.00 | N/A |
| Revenue This Year | $21.91 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $52.74 | ★ N/A |
| Revenue Growth | ★ 61.35 | N/A |
| 52 Week Low | $9.67 | $2.60 |
| 52 Week High | $54.70 | $10.31 |
| Indicator | IDR | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 71.98 |
| Support Level | $31.22 | $8.58 |
| Resistance Level | $39.88 | $9.85 |
| Average True Range (ATR) | 3.18 | 0.66 |
| MACD | 0.50 | 0.13 |
| Stochastic Oscillator | 68.52 | 86.62 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.